SCHEMBL2276305

SCHEMBL2276305

CNC(=O)CN(C)c1cccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2cc(OC)cc3cccnc23)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 3/20 0.51
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
TDP1 Q9NUW8 4/20 0.49
POLB P06746 1/20 0.49
PIK3CG P48736 9/20 0.49
PIK3CD O00329 4/20 0.47
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
CXCR2 P25025 1/20 0.45
AGTR1 P30556 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GLO1 Q04760 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279150 0.85 PIK3CG (0.55) PIK3CGPIK3CDMAPT
SCHEMBL188577 0.84 PIK3CG (0.68) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL2277780 0.83 MEN1 (0.54) MEN1KMT2APIK3CGPIK3CDLMNA
SCHEMBL3811843 0.82 SLC40A1 (0.74) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL188664 0.81 SLC40A1 (0.62) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL2276298 0.81 PIK3CG (0.53) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL3757518 0.81 PIK3CG (0.59) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL13452220 0.80 SLC40A1 (0.60) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL3757523 0.79 SLC40A1 (0.53) SLC40A1MEN1KMT2ATDP1POLB
SCHEMBL1792647 0.78 SLC40A1 (0.51) SLC40A1MEN1KMT2ATDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207712-A1 Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use EXELIXIS, INC. (US) 2011-08-25 US claimed
EP-2364974-A1 N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors Exelixis, Inc. (US) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207712-A1 Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use PIK3CA, PIK3CB, PIK3CG SLC40A1 4503/4885MEN1 3161/4885KMT2A 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.